Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03910387 · ClinicalTrials.gov registry record · Phase 2
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03910387: Completed Phase 2 study, sponsored by Emory University.
NCT03910387 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03910387, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.
Primary Outcome
Weight stability will be documented as percent weight change at 3 months compared to baseline.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Telotristat Ethyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-04-17 |
| Est. Completion | 2022-06-29 |
| Phase | Phase 2 |
What the finished NCT03910387 record still lists
NCT03910387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT03910387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03910387 about?
NCT03910387 is a clinical study titled "Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer". This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may ...
What is the current status of trial NCT03910387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2019-04-17. Estimated completion is 2022-06-29.
What interventions are being tested in trial NCT03910387?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Telotristat Ethyl (DRUG).
Who is sponsoring clinical trial NCT03910387?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03910387's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI